Search

Your search keyword '"Fliser, D"' showing total 872 results
Start Over Author "Fliser, D"
872 results on '"Fliser, D"'

1. Real-Life Anemia Management Among Patients with Non-Dialysis-Dependent Chronic Kidney Disease in Three European Countries

Author

Fliser D, Mata Lorenzo M, Houghton K, Ainsworth C, Blogg M, González de Antona Sánchez E, and Portoles J

Subjects
anemia, chronic kidney disease, clinical care process, erythropoiesis-stimulating agents, iron therapy, real-life management, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Danilo Fliser,1 Maria Mata Lorenzo,2 Katherine Houghton,3 Claire Ainsworth,3 Martin Blogg,2 Elena González de Antona Sánchez,4 Jose Portoles5 1Saarland University Medical Center, Homburg, Germany; 2Astellas Pharma Europe Ltd., Addlestone, UK; 3RTI Health Solutions, Manchester, UK; 4Astellas Pharma España S.A., Madrid, Spain; 5Hospital Universitario Puerta de Hierro, Madrid, SpainCorrespondence: Danilo Fliser, Saarland University Medical Center, Homburg, Germany, Tel +49 – 6841 – 16 15040, Fax +49 – 6841 – 16 15454, Email danilo.fliser@uks.euBackground: Anemia is prevalent among patients with chronic kidney disease (CKD), yet current evidence indicates that treatment may not adhere to Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. We aimed to document the management of patients with non-dialysis-dependent (NDD)-CKD receiving erythropoiesis-stimulating agent (ESA) therapy in Europe.Methods: This retrospective, observational study extracted information from medical records in Germany, Spain, and the UK. Eligible patients were adults with NDD-CKD stages 3b– 5 who initiated ESA therapy for anemia between January and December 2015. Anemia was defined as hemoglobin (Hb) < 13.0 g/dL (males) or < 12.0 g/dL (females). Data regarding ESA treatment, treatment response, concomitant iron therapy and blood transfusions were extracted up to 24 months post-ESA initiation, and data on CKD progression until abstraction date.Results: Eight hundred and forty-eight medical records were abstracted. Approximately 40% received no iron therapy prior to ESA initiation. At ESA initiation, mean ± standard deviation Hb level was 9.8 ± 1.0 g/dL. Most patients received darbepoetin alfa, and switching between ESAs was rare (8.5% of patients). Concomitant intravenous and oral iron therapy was prescribed for 36% and 42% of patients, respectively, during initial ESA therapy. Mean Hb levels reached the target level (10– 12 g/dL) within 3– 6 months of ESA initiation. Hb, transferrin saturation, and ferritin levels were infrequently monitored from 3 months post-ESA initiation. Rates of blood transfusion, dialysis, and diagnosis of end-stage renal disease were 16.4%, 19.3%, and 24.6%, respectively. Rates of kidney transplant and death were 4.8% and 8.8%, respectively.Conclusion: Among ESA-treated patients, ESA initiation was in accordance with KDIGO guidelines, but subsequent monitoring of Hb and iron deficiency were suboptimal.Graphical Abstract: Keywords: anemia, chronic kidney disease, clinical care process, erythropoiesis-stimulating agents, iron therapy, real-life management

Published
2023

8. Nicht-Vitamin-K-abhängige orale Antikoagulanzien (NOAK) bei chronischer Niereninsuffizienz: Empfehlungen der Arbeitsgemeinschaft „Herz – Niere“, der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung und der Deutschen Gesellschaft für Nephrologie

Author

Schlieper, G., Remppis, A., Schwenger, V., Keller, T., Dechend, R., Massberg, S., Baldus, S., Weinreich, T., Hetzel, G., Floege, J., Hoyer, J., Mahfoud, F., and Fliser, D.

Published
2018
Full Text
View/download PDF

10. From WEDA to EDTA to ERA: 60 years of supporting European nephrology and counting

Author

Wanner, C., Fliser, D., Rychlik, I., Torra, R., Gansevoort, R., Ortiz, A., Sarafidis, P., Ong, A., Cozzolino, M., Rosenkranz, A., Tuglular, S.Z., Gambaro, G., Fontana, M., Azzolini, L., and Vinck, C.

Subjects
Settore MED/14 - Nefrologia, Transplantation, treatment, kidney disease, burden of disease, outcomes, kidney failure, nephrology, prevention, renal replacement therapy, Europe, Renal Dialysis, Nephrology, Humans, Edetic Acid, Societies, Medical
Published
2022

11. Lipide und PCSK9-Inhibition bei chronischer Nierenerkrankung

Author

Schunk, S. J., Fliser, D., and Speer, T.

Abstract

Die Prävalenz der chronischen Nierenerkrankungen (CKD) nimmt weltweit stetig zu. Chronisch Nierenkranke weisen eine massiv erhöhte kardiovaskuläre Mortalität auf. Unter anderem spielen Lipoproteine eine wichtige Rolle bei der Entstehung atherosklerotischer kardiovaskulärer Erkrankungen. Bei urämischen Patienten sind Lipoproteine in ihrer Struktur verändert, was Auswirkungen auf deren biologische Funktion hat. Dies betrifft nicht nur LDL („low-denity lipoprotein“), sondern auch HDL („high-density lipoprotein“), dessen vasoprotektive Eigenschaften in der Urämie verloren gehen, sodass es in ein gefäßschädigendes Lipoprotein transformiert wird. Darüber hinaus induzieren triglyzeridreiche Lipoproteine eine sterile Inflammationsreaktion, woraus ebenfalls Gefäß- und Organschädigungen resultieren können. 2019 wurden von der European Society of Cardiology (ESC) und der European Atherosclerosis Society (EAS) neue Leitlinien zur Therapie von Dyslipidämien mit neuen LDL-Cholesterin(LDL-C)-Zielwerten vorgestellt. Insgesamt wird eine deutlich striktere LDL-C-Einstellung empfohlen. Neben lebensstilmodifizierenden Maßnahmen und Statinen/Ezetimibe, steht mit den PCSK9(Proproteinkonvertase Subtilisin/Kexin Typ 9)-Inhibitoren eine vielversprechende zusätzliche therapeutische Option zur Verfügung. Bei Patienten mit gering- oder mittelgradig eingeschränkter Nierenfunktion ist die Therapie mit PCSK9-Inhibitoren ähnlich erfolgreich und sicher wie in der Allgemeinbevölkerung. Leider fehlen entsprechende Daten für Patienten mit fortgeschrittener Nierenfunktionseinschränkung. Insgesamt spielt bei Nierenkranken die Senkung von LDL‑C eine zentrale Rolle in der kardiovaskulären Primär- und Sekundärprävention.

Published
2024
Full Text
View/download PDF

15. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

Author

Visseren, F, Mach, F, Smulders, Y, Carballo, D, Koskinas, K, Back, M, Benetos, A, Biffi, A, Boavida, J, Capodanno, D, Cosyns, B, Crawford, C, Davos, C, Desormais, I, Di Angelantonio, E, Duran, O, Halvorsen, S, Richard Hobbs, F, Hollander, M, Jankowska, E, Michal, M, Sacco, S, Sattar, N, Tokgozoglu, L, Tonstad, S, Tsioufis, K, van Dis, I, van Gelder, I, Wanner, C, Williams, B, De Backer, G, Regitz-Zagrosek, V, Aamodt, A, Abdelhamid, M, Aboyans, V, Albus, C, Asteggiano, R, Borger, M, Brotons, C, Celutkiene, J, Cifkova, R, Cikes, M, Cosentino, F, Dagres, N, De Backer, T, De Bacquer, D, Delgado, V, Ruijter, H, Dendale, P, Drexel, H, Falk, V, Fauchier, L, Ference, B, Ferrieres, J, Ferrini, M, Fisher, M, Fliser, D, Fras, Z, Gaita, D, Giampaoli, S, Gielen, S, Graham, I, Jennings, C, Jorgensen, T, Kautzky-Willer, A, Kavousi, M, Koenig, W, Konradi, A, Kotecha, D, Landmesser, U, Lettino, M, Lewis, B, Linhart, A, Lochen, M, Makrilakis, K, Mancia, G, Marques-Vidal, P, Mcevoy, J, Mcgreavy, P, Merkely, B, Neubeck, L, Nielsen, J, Perk, J, Petersen, S, Petronio, A, Piepoli, M, Pogosova, N, Prescott, E, Ray, K, Reiner, Z, Richter, D, Ryden, L, Shlyakhto, E, Sitges, M, Sousa-Uva, M, Sudano, I, Tiberi, M, Touyz, R, Ungar, A, Monique Verschuren, W, Wiklund, O, Wood, D, Zamorano, J, Visseren F., Mach F., Smulders Y. M., Carballo D., Koskinas K. C., Back M., Benetos A., Biffi A., Boavida J. -M., Capodanno D., Cosyns B., Crawford C. A., Davos C. H., Desormais I., Di Angelantonio E., Duran O. H. F., Halvorsen S., Richard Hobbs F. D., Hollander M., Jankowska E. A., Michal M., Sacco S., Sattar N., Tokgozoglu L., Tonstad S., Tsioufis K. P., van Dis I., van Gelder I. C., Wanner C., Williams B., De Backer G., Regitz-Zagrosek V., Aamodt A. H., Abdelhamid M., Aboyans V., Albus C., Asteggiano R., Borger M. A., Brotons C., Celutkiene J., Cifkova R., Cikes M., Cosentino F., Dagres N., De Backer T., De Bacquer D., Delgado V., Ruijter H. D., Dendale P., Drexel H., Falk V., Fauchier L., Ference B. A., Ferrieres J., Ferrini M., Fisher M., Fliser D., Fras Z., Gaita D., Giampaoli S., Gielen S., Graham I., Jennings C., Jorgensen T., Kautzky-Willer A., Kavousi M., Koenig W., Konradi A., Kotecha D., Landmesser U., Lettino M., Lewis B. S., Linhart A., Lochen M. -L., Makrilakis K., Mancia G., Marques-Vidal P., McEvoy J. W., McGreavy P., Merkely B., Neubeck L., Nielsen J. C., Perk J., Petersen S. E., Petronio A. S., Piepoli M., Pogosova N. G., Prescott E. I. B., Ray K. K., Reiner Z., Richter D. J., Ryden L., Shlyakhto E., Sitges M., Sousa-Uva M., Sudano I., Tiberi M., Touyz R. M., Ungar A., Monique Verschuren W. M., Wiklund O., Wood D., Zamorano J. L., Visseren, F, Mach, F, Smulders, Y, Carballo, D, Koskinas, K, Back, M, Benetos, A, Biffi, A, Boavida, J, Capodanno, D, Cosyns, B, Crawford, C, Davos, C, Desormais, I, Di Angelantonio, E, Duran, O, Halvorsen, S, Richard Hobbs, F, Hollander, M, Jankowska, E, Michal, M, Sacco, S, Sattar, N, Tokgozoglu, L, Tonstad, S, Tsioufis, K, van Dis, I, van Gelder, I, Wanner, C, Williams, B, De Backer, G, Regitz-Zagrosek, V, Aamodt, A, Abdelhamid, M, Aboyans, V, Albus, C, Asteggiano, R, Borger, M, Brotons, C, Celutkiene, J, Cifkova, R, Cikes, M, Cosentino, F, Dagres, N, De Backer, T, De Bacquer, D, Delgado, V, Ruijter, H, Dendale, P, Drexel, H, Falk, V, Fauchier, L, Ference, B, Ferrieres, J, Ferrini, M, Fisher, M, Fliser, D, Fras, Z, Gaita, D, Giampaoli, S, Gielen, S, Graham, I, Jennings, C, Jorgensen, T, Kautzky-Willer, A, Kavousi, M, Koenig, W, Konradi, A, Kotecha, D, Landmesser, U, Lettino, M, Lewis, B, Linhart, A, Lochen, M, Makrilakis, K, Mancia, G, Marques-Vidal, P, Mcevoy, J, Mcgreavy, P, Merkely, B, Neubeck, L, Nielsen, J, Perk, J, Petersen, S, Petronio, A, Piepoli, M, Pogosova, N, Prescott, E, Ray, K, Reiner, Z, Richter, D, Ryden, L, Shlyakhto, E, Sitges, M, Sousa-Uva, M, Sudano, I, Tiberi, M, Touyz, R, Ungar, A, Monique Verschuren, W, Wiklund, O, Wood, D, Zamorano, J, Visseren F., Mach F., Smulders Y. M., Carballo D., Koskinas K. C., Back M., Benetos A., Biffi A., Boavida J. -M., Capodanno D., Cosyns B., Crawford C. A., Davos C. H., Desormais I., Di Angelantonio E., Duran O. H. F., Halvorsen S., Richard Hobbs F. D., Hollander M., Jankowska E. A., Michal M., Sacco S., Sattar N., Tokgozoglu L., Tonstad S., Tsioufis K. P., van Dis I., van Gelder I. C., Wanner C., Williams B., De Backer G., Regitz-Zagrosek V., Aamodt A. H., Abdelhamid M., Aboyans V., Albus C., Asteggiano R., Borger M. A., Brotons C., Celutkiene J., Cifkova R., Cikes M., Cosentino F., Dagres N., De Backer T., De Bacquer D., Delgado V., Ruijter H. D., Dendale P., Drexel H., Falk V., Fauchier L., Ference B. A., Ferrieres J., Ferrini M., Fisher M., Fliser D., Fras Z., Gaita D., Giampaoli S., Gielen S., Graham I., Jennings C., Jorgensen T., Kautzky-Willer A., Kavousi M., Koenig W., Konradi A., Kotecha D., Landmesser U., Lettino M., Lewis B. S., Linhart A., Lochen M. -L., Makrilakis K., Mancia G., Marques-Vidal P., McEvoy J. W., McGreavy P., Merkely B., Neubeck L., Nielsen J. C., Perk J., Petersen S. E., Petronio A. S., Piepoli M., Pogosova N. G., Prescott E. I. B., Ray K. K., Reiner Z., Richter D. J., Ryden L., Shlyakhto E., Sitges M., Sousa-Uva M., Sudano I., Tiberi M., Touyz R. M., Ungar A., Monique Verschuren W. M., Wiklund O., Wood D., and Zamorano J. L.

Published
2021

19. Arterielle Hypertonie

Author

Fliser, D., Ritz, E., Steinbeck, Gerhard, editor, Paumgartner, Gustav, editor, Brandt, T., editor, Göke, B., editor, Greten, N., editor, Hiddemann, W., editor, Lode, H., editor, Mann, K., editor, Riess, H., editor, Risler, T., editor, Schattenkirchner, M., editor, Seeger, W., editor, and Wehling, M., editor

Published
2005
Full Text
View/download PDF

22. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

Author

Visseren, F, Mach, F, Smulders, Y, Carballo, D, Koskinas, K, Bäck, M, Benetos, A, Biffi, A, Boavida, J, Capodanno, D, Cosyns, B, Crawford, C, Davos, C, Desormais, I, Di Angelantonio, E, Franco, O, Halvorsen, S, Hobbs, F, Hollander, M, Jankowska, E, Michal, M, Sacco, S, Sattar, N, Tokgozoglu, L, Tonstad, S, Tsioufis, K, van Dis, I, van Gelder, I, Wanner, C, Williams, B, De Backer, G, Regitz-Zagrosek, V, Aamodt, A, Abdelhamid, M, Aboyans, V, Albus, C, Asteggiano, R, Borger, M, Brotons, C, Celutkiene, J, Cifkova, R, Cikes, M, Cosentino, F, Dagres, N, De Backer, T, De Bacquer, D, Delgado, V, Den Ruijter, H, Dendale, P, Drexel, H, Falk, V, Fauchier, L, Ference, B, Ferrières, J, Ferrini, M, Fisher, M, Fliser, D, Fras, Z, Gaita, D, Giampaoli, S, Gielen, S, Graham, I, Jennings, C, Jorgensen, T, Kautzky-Willer, A, Kavousi, M, Koenig, W, Konradi, A, Kotecha, D, Landmesser, U, Lettino, M, Lewis, B, Linhart, A, Lochen, M, Makrilakis, K, Mancia, G, Marques-Vidal, P, Mcevoy, J, Mcgreavy, P, Merkely, B, Neubeck, L, Nielsen, J, Perk, J, Petersen, S, Petronio, A, Piepoli, M, Pogosova, N, Prescott, E, Ray, K, Reiner, Z, Richter, D, Rydén, L, Shlyakhto, E, Sitges, M, Sousa-Uva, M, Sudano, I, Tiberi, M, Touyz, R, Ungar, A, Verschuren, W, Wiklund, O, Wood, D, Zamorano, J, Visseren, FLJ, Smulders, YM, Koskinas, KC, Boavida, JM, Davos, CH, Franco, OH, Hobbs, FDR, Jankowska, EA, Tsioufis, KP, van Gelder, IC, Aamodt, AH, Borger, MA, Ference, BA, Lewis, BS, Lochen, ML, McEvoy, JW, McGreavy, P, Nielsen, JC, Petersen, SE, Petronio, AS, Pogosova, NG, Prescott, EIB, Ray, KK, Richter, DJ, Touyz, RM, Verschuren, WMM, Zamorano, JL, Visseren, F, Mach, F, Smulders, Y, Carballo, D, Koskinas, K, Bäck, M, Benetos, A, Biffi, A, Boavida, J, Capodanno, D, Cosyns, B, Crawford, C, Davos, C, Desormais, I, Di Angelantonio, E, Franco, O, Halvorsen, S, Hobbs, F, Hollander, M, Jankowska, E, Michal, M, Sacco, S, Sattar, N, Tokgozoglu, L, Tonstad, S, Tsioufis, K, van Dis, I, van Gelder, I, Wanner, C, Williams, B, De Backer, G, Regitz-Zagrosek, V, Aamodt, A, Abdelhamid, M, Aboyans, V, Albus, C, Asteggiano, R, Borger, M, Brotons, C, Celutkiene, J, Cifkova, R, Cikes, M, Cosentino, F, Dagres, N, De Backer, T, De Bacquer, D, Delgado, V, Den Ruijter, H, Dendale, P, Drexel, H, Falk, V, Fauchier, L, Ference, B, Ferrières, J, Ferrini, M, Fisher, M, Fliser, D, Fras, Z, Gaita, D, Giampaoli, S, Gielen, S, Graham, I, Jennings, C, Jorgensen, T, Kautzky-Willer, A, Kavousi, M, Koenig, W, Konradi, A, Kotecha, D, Landmesser, U, Lettino, M, Lewis, B, Linhart, A, Lochen, M, Makrilakis, K, Mancia, G, Marques-Vidal, P, Mcevoy, J, Mcgreavy, P, Merkely, B, Neubeck, L, Nielsen, J, Perk, J, Petersen, S, Petronio, A, Piepoli, M, Pogosova, N, Prescott, E, Ray, K, Reiner, Z, Richter, D, Rydén, L, Shlyakhto, E, Sitges, M, Sousa-Uva, M, Sudano, I, Tiberi, M, Touyz, R, Ungar, A, Verschuren, W, Wiklund, O, Wood, D, Zamorano, J, Visseren, FLJ, Smulders, YM, Koskinas, KC, Boavida, JM, Davos, CH, Franco, OH, Hobbs, FDR, Jankowska, EA, Tsioufis, KP, van Gelder, IC, Aamodt, AH, Borger, MA, Ference, BA, Lewis, BS, Lochen, ML, McEvoy, JW, McGreavy, P, Nielsen, JC, Petersen, SE, Petronio, AS, Pogosova, NG, Prescott, EIB, Ray, KK, Richter, DJ, Touyz, RM, Verschuren, WMM, and Zamorano, JL

Published
2022

23. Arterielle Hypertonie

Author

Ritz, E., Fliser, D., Paumgartner, Gustav, editor, Brandt, Th., editor, Greten, H., editor, Koch, K. M., editor, Lode, H., editor, van de Loo, J., editor, Schattenkirchner, M., editor, Seeger, W., editor, Steinbeck, G., editor, and Ziegler, R., editor

Published
1999
Full Text
View/download PDF

24. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

Author

Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Back, M., Benetos, A., Biffi, A., Boavida, J. -M., Capodanno, D., Cosyns, B., Crawford, C., Davos, C. H., Desormais, I., DI Angelantonio, E., Franco, O. H., Halvorsen, S., Hobbs, F. D. R., Hollander, M., Jankowska, E. A., Michal, M., Sacco, S., Sattar, N., Tokgozoglu, L., Tonstad, S., Tsioufis, K. P., Van DIs, I., Van Gelder, I. C., Wanner, C., Williams, B., De Backer, G., Regitz-Zagrosek, V., Aamodt, A. H., Abdelhamid, M., Aboyans, V., Albus, C., Asteggiano, R., Borger, M. A., Brotons, C., Ielutkiene, J., Cifkova, R., Cikes, M., Cosentino, F., Dagres, N., De Backer, T., De Bacquer, D., Delgado, V., Den Ruijter, H., Dendale, P., Drexel, H., Falk, V., Fauchier, L., Ference, B. A., Ferrieres, J., Ferrini, M., Fisher, M., Fliser, D., Fras, Z., Gaita, D., Giampaoli, S., Gielen, S., Graham, I., Jennings, C., Jorgensen, T., Kautzky-Willer, A., Kavousi, M., Koenig, W., Konradi, A., Kotecha, D., Landmesser, U., Lettino, M., Lewis, B. S., Linhart, A., Lochen, M. -L., Makrilakis, K., Mancia, G., Marques-Vidal, P., Mcevoy, J. W., Mcgreavy, P., Merkely, B., Neubeck, L., Nielsen, J. C., Perk, J., Petersen, S. E., Petronio, A. S., Piepoli, M., Pogosova, N. G., Prescott, E. I. B., Ray, K. K., Reiner, Z., Richter, D. J., Ryden, L., Shlyakhto, E., Sitges, M., Sousa-Uva, M., Sudano, I., Tiberi, M., Touyz, R. M., Ungar, A., Verschuren, W. M. M., Wiklund, O., Wood, D., Zamorano, J. L., Crawford, C. A., Franco Duran, O. H., Richard Hobbs, F. D., Dis, I. V., Group, ESC Scientific Document, Clinical sciences, Cardio-vascular diseases, and Cardiology

Subjects
medicine.medical_specialty, Epidemiology, Population, air pollution, population, Guidelines, blood pressure, climate change, diabetes, healthy lifestyle, lifetime benefit, lifetime risk, lipids, nutrition, personalized, prevention, psychosocial factors, risk estimation, risk management, shared decision-making, smoking, stepwise approach, Risk Assessment, Humans, Primary Prevention, Risk Factors, Cardiovascular Diseases, Diabetes mellitus, medicine, Intensive care medicine, education, 610 Medicine & health, Risk management, education.field_of_study, business.industry, medicine.disease, Clinical Practice, Blood pressure, guidelines, Heart failure, Lifetime risk, Disease prevention, Cardiology and Cardiovascular Medicine, business, Stepwise approach, 360 Social problems & social services
Abstract

These are the clinical practice guidelines from the European Society of Cardiology on cardiovascular disease prevention in clinical practice, from 2021.

Published
2022

26. A randomized multicenter trial on a lung ultrasound-guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk see commentary

Author

Zoccali, C., Torino, C., Mallamaci, F., Sarafidis, P., Papagianni, A., Ekart, R., Hojs, R., Klinger, M., Letachowicz, K., Fliser, D., Seiler-Mussler, S., Lizzi, F., Wiecek, A., Miskiewicz, A., Siamopoulos, K., Balafa, O., Slotki, I., Shavit, L., Stavroulopoulos, A., Covic, A., Siriopol, D., Massy, Z.A., Seidowsky, A., Battaglia, Y., Martinez-Castelao, A., Polo-Torcal, C., Coudert-Krier, M.J., Rossignol, P., Fiaccadori, E., Regolisti, G., Hannedouche, T., Bachelet, T., Jager, K.J., Dekker, F.W., Tripepi, R., Tripepi, G., Gargani, L., Sicari, R., Picano, E., and London, G.M.

Subjects
cardiovascular risk, lung congestion, heart failure hemodialysis, chronic kidney failure, ESRD, lung ultrasound
Abstract

Lung congestion is a risk factor for all-cause and cardiovascular mortality in patients on chronic hemodialysis, and its estimation by ultrasound may be useful to guide ultrafiltration and drug therapy in this population. In an international, multi-center randomized controlled trial (NCT02310061) we investigated whether a lung ultrasound-guided treatment strategy improved a composite end point (all-cause death, non-fatal myocardial infarction, decompensated heart failure) vs usual care in patients receiving chronic hemodialysis with high cardiovascular risk. Patient-Reported Outcomes (Depression and the Standard Form 36 Quality of Life Questionnaire, SF36) were assessed as secondary outcomes. A total of 367 patients were enrolled: 183 in the active arm and 180 in the control arm. In the active arm, the pre-dialysis lung scan was used to titrate ultrafiltration during dialysis and drug treatment. Three hundred and seven patients completed the study: 152 in the active arm and 155 in the control arm. During a mean follow-up of 1.49 years, lung congestion was significantly more frequently relieved in the active (78%) than in the control (56%) arm and the intervention was safe. The primary composite end point did not significantly differ between the two study arms (Hazard Ratio 0.88; 95% Confidence Interval: 0.63-1.24). The risk for all-cause and cardiovascular hospitalization and the changes of left ventricular mass and function did not differ among the two groups. A post hoc analysis for recurrent episodes of decompensated heart failure (0.37; 0.15-0.93) and cardiovascular events (0.63; 0.41-0.97) showed a risk reduction for these outcomes in the active arm. There were no differences in patientreported outcomes between groups. Thus, in patients on chronic hemodialysis with high cardiovascular risk, a treatment strategy guided by lung ultrasound effectively relieved lung congestion but was not more effective than usual care in improving the primary or secondary end points of the trial.

Published
2021

36. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA

Author

Ortiz, A, Cozzolino, M, Duivenvoorden, R, Fliser, D, Fouque, D, Franssen, CFM, Goumenos, D, Hemmelder, MH, Hilbrands, LB, Jager, KJ, Massy, ZA, Noordzij, M, Rosenkranz, AR, Rychlik, I, Soler, MJ, Stevens, K, Torra, R, Tuglular, S, Vart, P, Wanner, C, Gansevoort, RT, ERA-EDTA Council, and Eracoda Working Grp

Subjects
risk factor, prevalence, COVID-19, mortality, renal replacement therapy, chronic kidney disease
Abstract

Diabetes, hypertension and cardiovascular disease have been listed as risk factors for severe coronavirus disease 2019 (COVID-19) since the first report of the disease in January 2020. However, this report did not mention chronic kidney disease (CKD) nor did it provide information on the relevance of estimated glomerular filtration rate (eGFR) or albuminuria. As the disease spread across the globe, information on larger populations with greater granularity on risk factors emerged. The recently published OpenSAFELY project analysed factors associated with COVID-19 death in 17 million patients. The picture that arose differs significantly from initial reports. For example, hypertension is not an independent risk factor for COVID-19 death [adjusted hazard ratio (aHR) 0.89], but renal disease very much is. Dialysis (aHR 3.69), organ transplantation (aHR 3.53) and CKD (aHR 2.52 for patients with eGFR

Published
2021

37. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA

Author

Ortiz, A., Cozzolino, M., Duivenvoorden, R., Fliser, D., Fouque, D., Franssen, C.F., Goumenos, D., Hemmelder, M.H., Hilbrands, L.B., Jager, K.J., Massy, Z.A., Noordzij, Marlies, Rosenkranz, A., Rychlık, I., Soler, M.J., Stevens, K., Torra, R., Tuglular, S., Vart, P., Wanner, C., Gansevoort, R.T., Ortiz, A., Cozzolino, M., Duivenvoorden, R., Fliser, D., Fouque, D., Franssen, C.F., Goumenos, D., Hemmelder, M.H., Hilbrands, L.B., Jager, K.J., Massy, Z.A., Noordzij, Marlies, Rosenkranz, A., Rychlık, I., Soler, M.J., Stevens, K., Torra, R., Tuglular, S., Vart, P., Wanner, C., and Gansevoort, R.T.

Abstract

Contains fulltext : 232029.pdf (Publisher’s version ) (Open Access)

Published
2021

43. Mild cognitive impairment and kidney disease: clinical aspects

Author

Viggiano, D. (Davide), Wagner, C.A. (Carsten), Blankestijn, P.J. (Peter), Bruchfeld, A. (Annette), Fliser, D. (Danilo), Fouque, D. (Denis), Frische, S. (Sebastian), Gesualdo, L. (Loreto), Gutiérrez, E. (Eugenio), Goumenos, D. (Dimitrios), Hoorn, E.J. (Ewout), Eckardt, K.-U. (Kai-Uwe), Knauß, S. (Samuel), König, M. (Maximilian), Malyszko, J. (Jolanta), Massy, Z. (Ziad), Nitsch, R. (Robert), Pesce, F. (Francesco), Rychlík, I. (Ivan), Soler, M.J. (Maria Jose), Spasovski, G. (Goce), Stevens, K.I. (Kathryn I.), Trepiccione, F. (Francesco), Wanner, C. (Christoph), Wiecek, A. (Andrzej), Zoccali, C. (Carmine), Unwin, R.J. (Robert John), Capasso, G. (Giovambattista), Viggiano, D. (Davide), Wagner, C.A. (Carsten), Blankestijn, P.J. (Peter), Bruchfeld, A. (Annette), Fliser, D. (Danilo), Fouque, D. (Denis), Frische, S. (Sebastian), Gesualdo, L. (Loreto), Gutiérrez, E. (Eugenio), Goumenos, D. (Dimitrios), Hoorn, E.J. (Ewout), Eckardt, K.-U. (Kai-Uwe), Knauß, S. (Samuel), König, M. (Maximilian), Malyszko, J. (Jolanta), Massy, Z. (Ziad), Nitsch, R. (Robert), Pesce, F. (Francesco), Rychlík, I. (Ivan), Soler, M.J. (Maria Jose), Spasovski, G. (Goce), Stevens, K.I. (Kathryn I.), Trepiccione, F. (Francesco), Wanner, C. (Christoph), Wiecek, A. (Andrzej), Zoccali, C. (Carmine), Unwin, R.J. (Robert John), and Capasso, G. (Giovambattista)

Published
2020
Full Text
View/download PDF

44. Mild cognitive impairment and kidney disease: clinical aspects

Author

Viggiano, D, Wagner, CA, Blankestijn, PJ, Bruchfeld, A, Fliser, D, Fouque, D, Frische, S, Gesualdo, L, Gutierrez, E, Goumenos, D, Hoorn, Ewout, Eckardt, KU, Knauss, S, Konig, M, Malyszko, J, Massy, Z, Nitsch, D, Pesce, F, Rychlik, I, Soler, MJ, Spasovski, G, Stevens, KI, Trepiccione, F, Wanner, C, Wiecek, A, Zoccali, C, Unwin, R, Capasso, G, Viggiano, D, Wagner, CA, Blankestijn, PJ, Bruchfeld, A, Fliser, D, Fouque, D, Frische, S, Gesualdo, L, Gutierrez, E, Goumenos, D, Hoorn, Ewout, Eckardt, KU, Knauss, S, Konig, M, Malyszko, J, Massy, Z, Nitsch, D, Pesce, F, Rychlik, I, Soler, MJ, Spasovski, G, Stevens, KI, Trepiccione, F, Wanner, C, Wiecek, A, Zoccali, C, Unwin, R, and Capasso, G

Published
2020

45. Nicht-Vitamin-K-abhängige orale Antikoagulanzien (NOAK) bei chronischer Niereninsuffizienz: Empfehlungen der Arbeitsgemeinschaft „Herz – Niere“, der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung und der Deutschen Gesellschaft für Nephrologie

Author

Massachusetts Institute of Technology. Institute for Medical Engineering & Science, Schlieper, G., Remppis, A., Schwenger, V., Keller, T., Dechend, R., Massberg, S., Baldus, S., Weinreich, T., Hetzel, G., Floege, J., Hoyer, J., Mahfoud, Felix, Fliser, D., Massachusetts Institute of Technology. Institute for Medical Engineering & Science, Schlieper, G., Remppis, A., Schwenger, V., Keller, T., Dechend, R., Massberg, S., Baldus, S., Weinreich, T., Hetzel, G., Floege, J., Hoyer, J., Mahfoud, Felix, and Fliser, D.

Abstract

Nicht-Vitamin-K-abhängige orale Antikoagulanzien (NOAK) werden zur Schlaganfallprophylaxe bei Vorhofflimmern mit entsprechendem Risikoscore sowie zur Therapie venöser thromboembolischer Ereignisse (wie tiefe Beinvenenthrombose und Lungenembolie) und deren Prophylaxe bei rezidivierenden Ereignissen eingesetzt. Die in Studien überwiegend an nierengesunden Patienten erhobenen Daten sind jedoch nicht immer auf Patienten mit chronischer Niereninsuffizienz übertragbar. NOAK sind bei höhergradiger Niereninsuffizienz nicht empfohlen bzw. kontraindiziert. Non-vitamin K antagonist oral anticoagulants (NOAC) are administered for stroke prophylaxis in patients with atrial fibrillation and corresponding risk scores. In addition, NOAC are used for treatment and prophylaxis of venous thromboembolic events, such as deep vein thrombosis and acute pulmonary embolism and their prophylaxis in recurrent events. Clinical trials have excluded patients with advanced chronic kidney disease; therefore, data cannot always be generalized to patients with chronic kidney disease. The use of NOAC is not recommended or is contraindicated in advanced stages of chronic kidney disease.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results